Health Pulse: Investors Shake Market, Bird Flu Looms & Drug Lists Debut

The health sector sees dynamic changes as Gerresheimer's shares rise due to activist investor interest, while Australia and New Zealand brace for a bird flu threat. The U.S. reveals $2 generic drugs list for Medicare, and Pfizer-BioNTech win a patent case in the UK. CeriBell targets a $578 million IPO valuation.

Shares of Gerresheimer surged following investment moves by activist Ricky Chad Sandler, while health officials in Australia and New Zealand are preparing for potential bird flu outbreaks. Measures include tighter biosecurity controls as they remain the last regions free from a deadly avian influenza strain.

The U.S. is set to release an affordable generic drugs list for Medicare recipients, aiming to cap prices at $2. In legal news, Pfizer and BioNTech successfully invalidated CureVac's vaccine patents in the UK, highlighting ongoing pharmaceutical competition.

Meanwhile, medical device maker CeriBell is looking to a significant IPO, targeting a robust valuation in response to investor interest. These developments underscore the dynamic landscape of the global health sector.

(With inputs from agencies.)